Showing 7391-7400 of 9550 results for "".
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Syneron Candela Expands Capabilities of UltraShape Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Powerhttps://practicaldermatology.com/news/20141117-syneron_candela_expands_capabilities_of_ultrashape_platform_receives_fda_clearance_for_the_new_u-sculpt_transducer_and_enhanced_ultrasound_power/2459064/The FDA cleared Syneron Medical Ltd.'s U-Sculpt transducer for the UltraShape non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for a 25 percent increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25 percen
- Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Boardhttps://practicaldermatology.com/news/20141106-dr_mary_lupo_joins_aquavit_pharmaceuticals_scientific_advisory_board/2459072/Mary Lupo, MD, FAAD has joined the US Scientific Advisory Board of Aquavit Pharmaceuticals. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened
- FDA Advisory Committee Recommends Approval of Secukinumab for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20141020-fda_advisory_committee_recommends_approval_of_secukinumab_for_moderate_to_severe_plaque_psoriasis/2459081/The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates
- Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercializationhttps://practicaldermatology.com/news/20141008-coronado_biosciences_forms_subsidiary_to_acquire_and_license_dermatology_products_for_commercialization/2459090/Coronado Biosciences, Inc. has formed a wholly owned subsidiary called, Journey Medical Corporation (JMC) to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid respons
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23
- Sirona Biochem: Obagi Medical Products Begins Manufacturing Scale-Up of Skin Lightening Agenthttps://practicaldermatology.com/news/20141008-sirona_biochem_obagi_medical_products_begins_manufacturing_scale-up_of_skin_lightening_agent/2459092/Sirona Biochem Corp. announced that its partner Obagi Medical Products Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International Inc., has started manufacturing scale-up of the skin lightening compound (TFC-849) originally developed by Sirona's scientists in Franc
- Peter Barton Hutt Appointed to Suneva Medical, Inc. Board Of Directorshttps://practicaldermatology.com/news/20141008-peter_barton_hutt_appointed_to_suneva_medical_inc_board_of_directors/2459093/Peter Barton Hutt was appointed a member of the Board of Directors of Suneva Medical, Inc., a privately-held aesthetics company. Mr. Hutt has specialized in food and drug law at the Washington, DC firm of Covington and Burling since 1960, pausing only to serve as Chief Counsel o
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- Ranbaxy Launches Absorica 25mg and 35mg Capsuleshttps://practicaldermatology.com/news/20141001-ranbaxy_launches_absorica_25mg_and_35mg_capsules/2459099/Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, launched Absorica (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. Absorica, according to the company, has become the most prescribe